Download PDF
Thromb Haemost 2022; 122(10): 1712-1722
DOI: 10.1055/a-1849-8477
Blood Cells, Inflammation and Infection

Hemorrhages in Polycythemia Vera and Essential Thrombocythemia: Epidemiology, Description, and Risk Factors—Learnings from a Large Cohort

Authors

  • Christophe Nicol

    1   Service d'Onco-Hématologie, Centre Hospitalier des Pays de Morlaix, Morlaix, France

  • Nadine Ajzenberg   *

    2   Laboratoire d'Hématologie, Hôpital Bichat, APHP, Paris, France

  • Karine Lacut

    3   Département de Médecine Interne et de Pneumologie, CHRU de Brest, Brest, France
    4   Inserm, UnivBrest, CHRU de Brest, UMR1304, GETBO, Brest, France

  • Francis Couturaud

    3   Département de Médecine Interne et de Pneumologie, CHRU de Brest, Brest, France
    4   Inserm, UnivBrest, CHRU de Brest, UMR1304, GETBO, Brest, France

  • Eric Lippert   *

    5   Laboratoire d'Hématologie, CHRU de Brest, Brest, France

  • Brigitte Pan-Petesch

    4   Inserm, UnivBrest, CHRU de Brest, UMR1304, GETBO, Brest, France
    6   Service d'Hématologie Clinique, Institut de Cancéro-Hématologie, CHRU de Brest, Brest, France

  • Jean-Christophe Ianotto   *

    4   Inserm, UnivBrest, CHRU de Brest, UMR1304, GETBO, Brest, France
    6   Service d'Hématologie Clinique, Institut de Cancéro-Hématologie, CHRU de Brest, Brest, France

Funding None.
Further Information
   Permissions and Reprints

Abstract

Background The management of myeloproliferative neoplasms (MPNs) is based on the reduction of thrombotic risk. The incidence, impact, and risk factors of bleedings have been less studied.

Methods All patients with polycythemia vera (n=339) or essential thrombocythemia (n=528) treated in our center are included in OBENE (Observatoire BrEstois des NEoplasies myéloprolifératives) cohort (NCT02897297). Major bleeding (MB) and clinically relevant nonmajor bleeding (CRNMB) occurring after diagnosis were included, except after leukemic transformation.

Results With a median follow-up of 8.3 years, incidence of hemorrhages was 1.85% patient/year, with an incidence of MB of 0.95% patient/year. The 10-year bleeding-free survival was 89%. The most frequent locations were digestive tract, “mouth, nose and throat,” and muscular hematoma. The case fatality rate of MB was 25%. The proportion of potentially avoidable postoperative bleeding was remarkable (17.6%). In multivariable analysis, eight risk factors of bleeding were identified: leukocytes >20 G/L at diagnosis (hazard ratio [HR]=5.13, 95% confidence interval [CI]: 1.77–14.86), secondary hemopathies (HR=2.99, 95% CI: 1.27–7.04), aspirin use at diagnosis (HR=2.11, 95% CI: 1.24–3.6), platelet count >1,000 G/L at diagnosis (HR=1.93, 95% CI: 1.11–3.36), history of hemorrhage (HR=1.82, 95% CI: 1.03–3.24), secondary cancers (HR=1.71, 95% CI: 1.01–2.89), atrial fibrillation (HR=1.66, 95% CI: 1.01–2.72), and male sex (HR=1.54, 95% CI: 1.02–2.33). The occurrence of a CRNMB increased the risk of a secondary MB (odds ratio=6.13, 95% CI: 2.86–12.6, p<0.00001). Most patients taking hydroxyurea displayed a nonmacrocytic median corpuscular value in the months preceding bleeding (51.4%).

Discussion The morbidity and mortality of bleedings in MPN should not be underestimated, and patients with platelet count >1,000 G/L and/or leukocytes >20 G/L, and possibly patients who suffered from a CRNMB could benefit from cytoreduction to reducing bleeding risk. Postoperative bleedings represent a substantial proportion of bleeding and could be better prevented.

Keywords

hemorrhage - polycythemia vera - essential thrombocythemia - risk factors

Author Contributions

C.N. and J.-C.I. elaborated the study, made statistics, and wrote the paper. B.P.-P., K.L., E.L., and N.A. critically reviewed the paper. F.C. helped in statistical analysis.


* France Intergroupe des Syndromes Myéloprolifératifs, Paris, France.


Supplementary Material



Publication History

Received: 17 September 2021

Accepted: 10 May 2022

Accepted Manuscript online:
11 May 2022

Article published online:
08 September 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany